This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 Nov 2011

Par Pharmaceutical Completes Acquisition of Anchen

Par Pharmaceutical Companies Inc. has announced the completion of the acquisition of privately-held Anchen Pharmaceuticals.

US-based speciality pharmaceutical company Par Pharmaceutical Companies recently announced the completion of its US$410m acquisition of Anchen Pharmaceuticals, a privately held generic drug maker.


California-based Anchen is a profitable, fully integrated pharmaceutical com-pany with five commercialised products, 27 AN-DAs on file with the US FDA, five of which are believed to be first-to-file, and approximately 26 additional products in development.


Anchen has approximately 200 employees and more than 72,000ft2 of expandable manufacturing and warehouse facilities with state-of-the-art equipment.


Through its wholly owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceut

Related News